Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 10/20 | 0.53 |
| ▸ | HTT | P42858 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 2/20 | 0.39 |
| ▸ | CCND1 | P24385 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10433225 | 0.83 | HTR6 (0.58) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL6205803 | 0.77 | HTR6 (0.62) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL6359369 | 0.76 | HTR6 (0.58) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL6457643 | 0.74 | HTR6 (0.57) | HTR6KMT2AALDH1A1MAPT | |
| SCHEMBL3994690 | 0.73 | ASAH1 (0.47) | HTR6HTTALDH1A1TSHRL3MBTL1 | |
| SCHEMBL3475552 | 0.73 | HTT (0.50) | HTR6HTTKMT2AALDH1A1LMNA | |
| SCHEMBL15554467 | 0.72 | KMT2A (0.57) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL29414068 | 0.72 | KMT2A (0.57) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL4065276 | 0.72 | HTR6 (0.61) | HTR6HTTMEN1KMT2AALDH1A1 | |
| SCHEMBL29558089 | 0.72 | HTR6 (0.61) | HTR6HTTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818639-B2 | COMBINATION OF A 5-HT2C RECEPTOR AGONIST AND A 5-HT6 RECEPTOR ANTAGONIST, OR A SALT, ENANTIOMER OR PRODRUG FORM | BIOVITRUM AB (SE) | 2004-11-16 | — | — | US | claimed |
| EP-1301476-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2003-04-16 | — | — | EP | claimed |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-06-06 | — | — | US | claimed |
| WO-2002008178-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2002-01-31 | — | — | WO | claimed |
| EP-2121601-B1 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2016-06-15 | — | — | EP | disclosed |
| US-8343964-B2 | Indolic derivatives, their preparation processes and their uses in particular as antibacterials | UNIVERSITE JOSEPH FOURIER (FR) | 2013-01-01 | — | — | US | disclosed |
| EP-2298738-B1 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2298738-A1 | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | Wyeth LLC (US) | 2011-03-23 | — | — | EP | disclosed |
| US-7838518-B2 | 1-arylsulfonyl-3-substituted indole and indoline derivatives useful in the treatment of central nervous system disorders | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | UNIVERSITE JOSEPH FOURIER (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2121601-A2 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | Université Joseph Fourier (FR) | 2009-11-25 | — | — | EP | disclosed |
| EP-2114878-A1 | 5-(HETEROCYCLYL)ALKYL-N-(ARYLSULFONYL)INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 LIGANDS | Suven Life Sciences Limited (IN) | 2009-11-11 | — | — | EP | disclosed |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2002-06-06 | — | — | US | disclosed |
| WO-2002032863-A1 | 2-, 3-, 4-, OR 5-SUBSTITUTED-N1-(BENZENSULFONYL)INDOLES AND THEIR USE IN THERAPY | BIOVITRUM AB (SE) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002008178-A1 | NEW COMBINATION OF SEROTONIN AGONIST (5HT2) AND ANTAGONIST (5HT6)AS PHARMACEUTICAL FORMULATION | BIOVITRUM AB (SE) | 2002-01-31 | — | — | WO | disclosed |
| US-5817651-A | ANALGESICS, RHEUMATIC DISEASES, ANTIINFLAMMATORY AGENTS | SANOFI (FR) | 1998-10-06 | — | — | US | disclosed |
| US-5607933-A | METHODS FOR TREATMENT OF GLAUCOMA AND FOR RELIEF OF PAIN AND RHEUMATIC AND INFLAMMATORY CONDITIONS BY ADMINISTERING THE INDOLES; N-HETERYL IS 2-PIPERAZINYL | STERLING WINTHROP INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5324737-A | Analgesics, antirheumatic and antiinflammatory agents, glaucoma | STERLING WINTHROP INC. (US) | 1994-06-28 | — | — | US | disclosed |
| US-5068234-A | Analgesics, rheumatic diseases, antiinflammatory agents or antiglaucoma | STERLING DRUG INC. (US) | 1991-11-26 | — | — | US | disclosed |
| EP-0444451-A2 | 3-Arylcarbonyl-1H-indoles useful as therapeutic agents | STERLING WINTHROP INC. (US) | 1991-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144726-A1 | NOVEL INDOLIC DERIVATIVES, THEIR PREPARATION PROCESSES AND THEIR USES IN PARTICULAR AS ANTIBACTERIALS | GPBAR1, TPH1, GPER1 | HTR6 138/4885HTT 2147/4885MEN1 3120/4885 |
| US-20020068732-A1 | Pharmaceutical combination formulation and method of treatment with the combination | HTR6, HTR5A, HTR2C | HTR6 1/4885HTT 429/4885MEN1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.